+ Watch INCY
on My Watchlist
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
Incyte is at an eight year high less than a year after what I believe was a fifteen year low last April. Kudos to anyone who had the foresight or at least the testicles to buy biotech during the meltdown last spring. But if you invested in Incyte back then, cash out and buy yourself something nice. The pipeline and partnerships have potential, but not 1.5 billion market cap potential at this time. Given the ebb and flow inherent in baby biotech, allow yourself a chance to buy it again below 5 next time the worm turns.
I was fortunate enough to get in at the right time and selling now is the wrong time if you are in this for the long term. However I have no problem with anyone taking their profits now and walking away because if you made a profit why not cash out? However if you are willing to wait it out the stock will hit 22 to 25 this year, higher if they gain FDA approval just on their drug for the treatment of MPD's. Incyte has a major advantage that other companies competing in the MPD related sector do not have a drug that is very effective in the treatment of MPD's. Only one other company, Targen a privately held company has an MPD treatment that is showing real clinical success but there is plenty of room for both drugs. The companies that recently announced agreements with Incyte know that if this drug continues to perform well and so far there is no reason to see why it won't FDA approval will come and drug will go to market. This could lead to huge sales for Incyte. Its still too early to know what the final story will be here but so far this drug is a winner. I would keep buying right now but as I said previously you can't fault anyone for taking a profit now.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions